RCS - ValiRx PLC - ValiRx to present at Shares Investor Meeting <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

11/12/2015 09:30

RNS Number : 7857I
ValiRx PLC
11 December 2015
ValiRx Plc
("ValiRx"or "theCompany")
"VALIRX TO PRESENT AT THE SHARES INVESTOR EVENING IN LONDON ON TUESDAY, 15 DECEMBER 2015"
London, UK, 11th December 2015: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that Satu Vainikka, Chief Executive will be presenting to investors at the free-to-attend Shares Investor Evening in London on Tuesday, 15 December 2015.
The Investor Evening will take place at Novotel Tower Bridge, 10 Pepys Street, London, EC3N 2NR between 18:00 and 20:30 with presentations starting at 18:30.
The Shares Investor Evenings are designed to showcase dynamiccompanies and provide an opportunity for investors to meet directly with management.
For more information, visithttp://www.sharesmagazine.co.uk/events/event/shares-investor-evening-15-dec-15/presenting/
*** ENDS ***
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka
www.valirx.com


Northland Capital Partners Limited (Broker)
Tel: +44 (0) 20 7382 1100
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Abigail Wayne (Broking) 

Peckwater PR
Tel: +44 (0) 7879 458 364
Tarquin Edwards
tarquin.edwards@peckwaterpr.co.uk
Notes for Editors 
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed onthe Alternative Investment Market ("AIM") of the London StockExchange in October 2006.
The Company has a pipeline ofother therapeutic drugs, which are currently progressing towards clinicaltrials. The product focus is in the targeted analysis and treatment of cancer,but thetechnologies can be applied to other fields as well, such as neurologyand inflammatory diseases. It actively manages projectswithin its portfolio as a trading company. The ValiRx business model spreads the risks of life science technologydevelopment by minimizing financial exposure andrunning a set of projects todefined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are thegreatest.
The Company operates through thefollowing divisional companies:
1. ValiPharma is the therapeuticsdivision, with two embedded technologies primarily directed at the treatment ofcancers.
2. ValiFinn is the biomarkers anddiagnostic development division. ValiRxacquired through its ValiFinn subsidiary, the complimentary TRAC technologylater in the year to strengthen the portfolio.
3. ValiSeek is a joint venturebetween ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentiallyother indications.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRALIFFAFELLLIE